文献速递妇科

分子分型对淋巴结分期且未接受辅助治疗的高级别子宫内膜癌患者的预后意义

Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
PubMed 文献 · Gynecol Oncol · 2022-01-23

该研究对丹麦妇科癌症数据库2005-2012年412例高级别子宫内膜癌进行分子分型,其中367例分析成功,251例接受淋巴结清扫。淋巴结清扫亚组5年复发率:p53abn 36.7%、POLEmut 0.0%、MMRd 13.4%、NSMP 42.9%(p<0.001)。未辅助治疗患者(n=264)中POLEmut(n=26)无一复发。结论:分子分型具有强预后价值,独立于临床病理因素。

要点

  • 淋巴结清扫亚组5年复发率:p53abn 36.7%、POLEmut 0.0%、MMRd 13.4%、NSMP 42.9%(p<0.001)。
  • 未辅助治疗患者(n=264)中POLEmut(n=26)无一复发。
  • 分子分型预后价值独立于临床病理因素,也见于淋巴结分期和未辅助治疗患者。

核心结论

  • 分子分型对高级别子宫内膜癌具有强预后价值,独立于临床病理因素,在淋巴结分期和未辅助治疗患者中同样成立。
  • 早期p53abn子宫内膜癌的不良预后并非由未发现的淋巴结转移所致,POLEmut子宫内膜癌的惰性行为独立于辅助治疗。

研究设计与样本

  • 对丹麦妇科癌症数据库(2005-2012)412例高级别子宫内膜癌进行POLE外切酶域突变DNA测序及错配修复蛋白和p53表达免疫组化,分型为POLE超突变(POLEmut)、错配修复缺陷(MMRd)、p53突变(p53abn)或无特定分子谱(NSMP)。
  • 排除IV期或术后残留病灶患者,分子分析成功367例,其中251例接受淋巴结清扫。
  • 采用Kaplan-Meier法、对数秩检验和Cox比例风险模型分析。

主要发现

  • 淋巴结清扫亚组5年复发率:p53abn 36.7%、POLEmut 0.0%、MMRd 13.4%、NSMP 42.9%(p<0.001)。
  • 在IA-IB期患者中观察到相似结果。
  • 未辅助治疗患者(n=264)中,POLEmut(n=26)无一复发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The clinical role of the molecular endometrial cancer (EC) classification has not been fully explored in patients staged with lymphadenectomy or without adjuvant treatment, conditions that could potentially moderate the prognostic value of the classification. We aimed to evaluate the clinical outcome of the molecular subgroups in patients with high-grade EC staged by lymphadenectomy and those without adjuvant treatment. METHODS: DNA-sequencing for the detection of pathogenic POLE-exonuclease domain mutations and immunohistochemistry for mismatch repair (MMR) proteins and p53 expression were performed on 412 high-grade EC from the Danish Gynaecological Cancer Database (2005-2012) to classify them as POLE-ultramutated (POLEmut), MMR-deficient (MMRd), p53-mutant (p53abn), or no specific molecular profile (NSMP). Patients with stage IV or residual disease after surgery were excluded. Kaplan-Meier method, log-rank test and Cox proportional hazard models were used for analysis. RESULTS: Molecular analysis was successful in 367 EC; 251 patients had undergone lymphadenectomy. Five-year recurrence rates in this subgroup of patients was 36.7% for women with p53abn EC, 0.0% for POLEmut EC, 13.4% for MMRd EC and 42.9% for NSMP EC (p < 0.001). Similar results were observed among stage IA-IB patients. Among patients without adjuvant treatment (n = 264), none with POLEmut EC (n = 26) had a recurrence. CONCLUSION: The molecular EC classification has strong prognostic value, independent of clinicopathological factors, also among high-grade EC patients staged by lymphadenectomy and those without adjuvant treatment. The unfavourable prognosis of early-stage p53abn EC is not due to undetected lymph node metastasis, and the indolent behaviour of POLEmut EC is independent of adjuvant treatment.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Leon-Castillo A, Horeweg N, Peters EEM, et al. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment. Gynecol Oncol. 2022. PMID: 35078648. doi:10.1016/j.ygyno.2022.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。